CLINICAL TRIALS PROFILE FOR CHIRHOSTIM
✉ Email this page to a colleague
All Clinical Trials for CHIRHOSTIM
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00587132 ↗ | Secretin (ChiRhoStim) Pancreas Perfusion for Pancreatic Adenocarcinoma | Terminated | ChiRhoClin, Inc. | Phase 1/Phase 2 | 2006-11-01 | The purpose of this study is to test if secretin-enhanced CT is a useful noninvasive screening tool for pancreatic cancer in a high-risk population. |
NCT00587132 ↗ | Secretin (ChiRhoStim) Pancreas Perfusion for Pancreatic Adenocarcinoma | Terminated | Mayo Clinic | Phase 1/Phase 2 | 2006-11-01 | The purpose of this study is to test if secretin-enhanced CT is a useful noninvasive screening tool for pancreatic cancer in a high-risk population. |
NCT01087801 ↗ | A Study of Synthetic Human Secretin (ChiRhoStim®) Administered Intravenously to Stimulate Exocrine Pancreas Fluid Secretion for Collection Via Endoscope and Laboratory Analysis of DNA Markers | Completed | ChiRhoClin, Inc. | Phase 3 | 2007-10-01 | The following are the study hypothesis: - Secretin administration compared to placebo will result in a statistically significantly greater percentage of collected fluid samples being predominantly of exocrine pancreas origin when samples are duodenal aspirates. - Secretin administration compared to placebo will result in a statistically significantly greater percentage of collected fluid samples meeting the minimum specifications for use in the indicated laboratory test of DNA mutational analysis. |
NCT01265875 ↗ | Secretin Infusion for Pain Due to Chronic Pancreatitis | Completed | Dartmouth-Hitchcock Medical Center | Phase 1/Phase 2 | 2010-12-01 | - To determine if intravenous secretin administration in escalating doses three times daily for three days will improve the pain from CP at the time of infusion, after each infusion (1 to 3 hours), at Day 7 after infusion, and at Day 30 after infusion. - To validate the safety of intravenous secretin administration at the dosage indicated in this study. |
NCT01265875 ↗ | Secretin Infusion for Pain Due to Chronic Pancreatitis | Completed | ChiRhoClin, Inc. | Phase 1/Phase 2 | 2010-12-01 | - To determine if intravenous secretin administration in escalating doses three times daily for three days will improve the pain from CP at the time of infusion, after each infusion (1 to 3 hours), at Day 7 after infusion, and at Day 30 after infusion. - To validate the safety of intravenous secretin administration at the dosage indicated in this study. |
NCT02869893 ↗ | MRCP: A Reliable, Non Invasive Method for Staging Chronic Pancreatitis in Pediatrics | Completed | ChiRhoClin, Inc. | N/A | 2016-08-10 | The goal of this research study is to learn more about the pancreas. The investigators want to use Magnetic Resonance Cholangiopancreatography (MRCP) to learn more about the size of a normal pancreas. MRCP is a special kind of MRI exam that produces detailed images of the pancreas. The investigators also want to figure out how much fluid the pancreas releases in response to secretin. Secretin is a chemical in the body that causes the pancreas to release fluid that helps with digestion. Secretin is used during the MRCP (MR-PFT) to help identify dysfunction of the pancreas. MR elastography (MRE) will be used to measure how hard the pancreas is. MRE is a special kind of MRI that uses vibrations to image tissue. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for CHIRHOSTIM
Condition Name
Clinical Trial Locations for CHIRHOSTIM
Trials by Country
Clinical Trial Progress for CHIRHOSTIM
Clinical Trial Phase
Clinical Trial Sponsors for CHIRHOSTIM
Sponsor Name